Literature DB >> 25453268

Clinical applications of pulmonary delivery of antibiotics.

Patrick A Flume1, Donald R VanDevanter2.   

Abstract

The treatment of infection typically involves administration of antibiotics by a systemic route, such as intravenous or oral. However, pulmonary infections can also be approached by inhalation of antibiotics as the infection is more directly accessible via the airways, making inhalation delivery essentially topical administration. This approach offers deposition of high antimicrobial concentrations directly at the site of infection but with a potentially reduced systemic exposure. This review covers the evidence for aerosolized antibiotics for the treatment of a number of conditions such as cystic fibrosis (CF), where it has become the standard of care for chronic infection, as well as non-CF bronchiectasis, non-tuberculous mycobacteria, and ventilator-associated infection where such therapy does not have an approved indication but has been used with increasing frequency.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aerosol; Bronchiectasis; Cystic fibrosis; Inhaled antibiotics; Mycobacteria; Pneumocystis

Mesh:

Substances:

Year:  2014        PMID: 25453268      PMCID: PMC4406777          DOI: 10.1016/j.addr.2014.10.009

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  87 in total

Review 1.  Mucolytics for bronchiectasis.

Authors:  A J Crockett; J M Cranston; K M Latimer; J H Alpers
Journal:  Cochrane Database Syst Rev       Date:  2001

2.  Aerosol therapy in mechanically ventilated patients: recent advances and new techniques.

Authors:  J B Fink; R Dhand
Journal:  Semin Respir Crit Care Med       Date:  2000       Impact factor: 3.119

3.  Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

Authors:  Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson
Journal:  J Pediatr       Date:  2007-06-22       Impact factor: 4.406

4.  Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis.

Authors:  J Bradley; O McAlister; S Elborn
Journal:  Eur Respir J       Date:  2001-04       Impact factor: 16.671

5.  Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.

Authors:  G Taccetti; S Campana; F Festini; M Mascherini; G Döring
Journal:  Eur Respir J       Date:  2005-09       Impact factor: 16.671

6.  Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis.

Authors:  F Ratjen; G Comes; K Paul; H G Posselt; T O Wagner; K Harms
Journal:  Pediatr Pulmonol       Date:  2001-01

7.  Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis.

Authors:  Wanda J Kozlowska; Andrew Bush; Angela Wade; Paul Aurora; Siobhán B Carr; Rosie A Castle; Ah-Fong Hoo; Sooky Lum; John Price; Sarath Ranganathan; Clare Saunders; Sanja Stanojevic; John Stroobant; Colin Wallis; Janet Stocks
Journal:  Am J Respir Crit Care Med       Date:  2008-04-10       Impact factor: 21.405

Review 8.  Inhalation of antibiotics in cystic fibrosis.

Authors:  D J Touw; R W Brimicombe; M E Hodson; H G Heijerman; W Bakker
Journal:  Eur Respir J       Date:  1995-09       Impact factor: 16.671

9.  Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.

Authors:  M Ballmann; P Rabsch; H von der Hardt
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

Review 10.  Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management.

Authors:  Margaret Rosenfeld; Bonnie W Ramsey; Ronald L Gibson
Journal:  Curr Opin Pulm Med       Date:  2003-11       Impact factor: 3.155

View more
  14 in total

1.  Preclinical Pharmacokinetic and Pharmacodynamic Data To Support Cefoxitin Nebulization for the Treatment of Mycobacterium abscessus.

Authors:  Shachi Mehta; Vincent Aranzana-Climent; Blandine Rammaert; Nicolas Grégoire; Sandrine Marchand; William Couet; Julien M Buyck
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

2.  Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats. 4. Aztreonam.

Authors:  Sandrine Marchand; Nicolas Grégoire; Julien Brillault; Isabelle Lamarche; Patrice Gobin; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

3.  Understanding persistent bacterial lung infections: clinical implications informed by the biology of the microbiota and biofilms.

Authors:  Alexa A Pragman; John P Berger; Bryan J Williams
Journal:  Clin Pulm Med       Date:  2016-03

4.  Nebulized Gentamicin as an Alternative to Nebulized Tobramycin for Tracheitis in Pediatric Patients.

Authors:  Justin K Chen; Brittany L Martin-McNew; Lisa M Lubsch
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jan-Feb

5.  Tobramycin Serum Concentrations in Tracheostomy-Dependent Children Receiving Inhaled Tobramycin.

Authors:  Kaitlin M Hughes; A Ioana Cristea; Emma M Tillman
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2020-05-21       Impact factor: 0.885

6.  Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe.

Authors:  Muhammad-Hariri Mustafa; Hussein Chalhoub; Olivier Denis; Ariane Deplano; Anne Vergison; Hector Rodriguez-Villalobos; Michael M Tunney; J Stuart Elborn; Barbara C Kahl; Hamidou Traore; Francis Vanderbist; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

Review 7.  Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.

Authors:  Zarmina Ehsan; John P Clancy
Journal:  Future Microbiol       Date:  2015-11-17       Impact factor: 3.165

8.  Disease Models: Lung Models for Testing Drugs Against Inflammation and Infection.

Authors:  Patrick Carius; Justus C Horstmann; Cristiane de Souza Carvalho-Wodarz; Claus-Michael Lehr
Journal:  Handb Exp Pharmacol       Date:  2021

Review 9.  Insect antimicrobial peptides: potential weapons to counteract the antibiotic resistance.

Authors:  M D Manniello; A Moretta; R Salvia; C Scieuzo; D Lucchetti; H Vogel; A Sgambato; P Falabella
Journal:  Cell Mol Life Sci       Date:  2021-02-17       Impact factor: 9.261

Review 10.  Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient.

Authors:  Matteo Bassetti; Charles-Edouard Luyt; David P Nicolau; Jérôme Pugin
Journal:  Ann Intensive Care       Date:  2016-04-18       Impact factor: 6.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.